234 related articles for article (PubMed ID: 20159376)
1. Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102).
Biedenbach DJ; Rhomberg PR; Mendes RE; Jones RN
Diagn Microbiol Infect Dis; 2010 Mar; 66(3):301-7. PubMed ID: 20159376
[TBL] [Abstract][Full Text] [Related]
2. CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria.
Putnam SD; Castanheira M; Moet GJ; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2010 Apr; 66(4):393-401. PubMed ID: 20022192
[TBL] [Abstract][Full Text] [Related]
3. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.
Jones RN; Fritsche TR; Ge Y; Kaniga K; Sader HS
J Antimicrob Chemother; 2005 Dec; 56(6):1047-52. PubMed ID: 16239290
[TBL] [Abstract][Full Text] [Related]
5. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
6. In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States.
Jones RN; Mendes RE; Sader HS; Castanheira M
Clin Infect Dis; 2011 Jun; 52 Suppl 7():S477-86. PubMed ID: 21546624
[TBL] [Abstract][Full Text] [Related]
7. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
[TBL] [Abstract][Full Text] [Related]
8. Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008).
Castanheira M; Watters AA; Mendes RE; Farrell DJ; Jones RN
J Antimicrob Chemother; 2010 Jul; 65(7):1353-8. PubMed ID: 20430787
[TBL] [Abstract][Full Text] [Related]
9. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.
Sader HS; Jones RN; Stilwell MG; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):181-6. PubMed ID: 16105562
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada.
Pfaller MA; Castanheira M; Sader HS; Jones RN
Int J Antimicrob Agents; 2010 Mar; 35(3):282-7. PubMed ID: 20036520
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
Fritsche TR; Kirby JT; Jones RN
Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections.
Fritsche TR; Rhomberg PR; Sader HS; Jones RN
J Antimicrob Chemother; 2008 May; 61(5):1092-8. PubMed ID: 18310135
[TBL] [Abstract][Full Text] [Related]
14. Comparative antimicrobial spectrum and activity of BMS284756 (T-3811; a desfluoroquinolone) tested against an international collection of staphylococci and enterococci, including in vitro test development and intermethod comparisons.
Pfaller MA; Beach ML; Gordon KA; Jones RN
J Chemother; 2002 Feb; 14(1):13-8. PubMed ID: 11892893
[TBL] [Abstract][Full Text] [Related]
15. In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens.
Jones RN; Bell JM; Sader HS; Turnidge JD; Stilwell MG
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):434-9. PubMed ID: 19302927
[TBL] [Abstract][Full Text] [Related]
16. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
Fritsche TR; Sader HS; Stillwell MG; Jones RN
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):440-6. PubMed ID: 19302928
[TBL] [Abstract][Full Text] [Related]
18. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
19. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
